RxDoctor Payments Data

Martin Charlat, MD

Cardiovascular Disease · Encinitas, CANPI 1790753770

Payments from drug & device makers

$11,861in general payments, 2019–2025

Across 456 payments — averaging $26.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$1K
  • Amgen$929
  • Pfizer$858
  • E.r. Squibb & Sons, L.L.C.$704
  • Medtronic$678
  • Cvrx, Inc.$580
  • plus $7K from 40 others

What the payments were for

  • Food & beverage$11,861100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,861 in reported general payments places this provider in the 75th percentile of 2,184 cardiovascular disease providers in California.

See all cardiovascular disease providers in California

Medicare billing

Part B allowed, 2024
$751,666
Medicare patients
1,613
Services billed
9,067

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban246$329,408
Repatha SureclickEvolocumab183$231,912
EntrestoSacubitril/Valsartan67$110,193
Praluent PenAlirocumab75$73,944
FarxigaDapagliflozin Propanediol30$36,649
JardianceEmpagliflozin22$29,034
Repatha SyringeEvolocumab24$22,532
XareltoRivaroxaban21$22,156
Ezetimibe513$18,125
Rosuvastatin Calcium574$8,281
NexletolBempedoic Acid16$8,273
Metoprolol Succinate425$8,028
Atorvastatin Calcium654$7,303
Amlodipine Besylate550$5,592
Ranolazine ErRanolazine26$5,429

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$858$329,408246 claims
NovartisEntresto$1,122$110,19367 claims
AstraZenecaFarxiga$451$36,64930 claims
Boehringer IngelheimJardiance$328$29,03422 claims
Johnson & JohnsonXarelto$368$22,15621 claims
Esperion Therapeutics, Inc.Nexletol$501$8,27316 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,184 cardiovascular disease providers in California.

Other cardiovascular disease in Encinitas

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →